These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 6995687)

  • 1. Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.
    Pofi R; Bonaventura I; Duffy J; Maunsell Z; Shine B; Isidori AM; Tomlinson JW
    Endocr Connect; 2023 Aug; 12(9):. PubMed ID: 37410094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism.
    Sieber-Ruckstuhl NS; Reusch CE; Hofer-Inteeworn N; Kuemmerle-Fraune C; Müller C; Hofmann-Lehmann R; Boretti FS
    J Vet Intern Med; 2019 May; 33(3):1266-1271. PubMed ID: 30865322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma adrenocorticotropic hormone but not aldosterone is correlated with blood pressure in patients with aldosterone-producing adenomas.
    Kobayashi H; Haketa A; Takahiro U; Otsuka H; Tanaka S; Hatanaka Y; Ikeda Y; Abe M; Fukuda N; Soma M
    J Clin Hypertens (Greenwich); 2017 Mar; 19(3):280-286. PubMed ID: 27917596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Treating Primary Aldosteronism on Renal Function.
    Kramers BJ; Kramers C; Lenders JW; Deinum J
    J Clin Hypertens (Greenwich); 2017 Mar; 19(3):290-295. PubMed ID: 27659389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A urine-concentrating defect in 11β-hydroxysteroid dehydrogenase type 2 null mice.
    Evans LC; Livingstone DE; Kenyon CJ; Jansen MA; Dear JW; Mullins JJ; Bailey MA
    Am J Physiol Renal Physiol; 2012 Aug; 303(4):F494-502. PubMed ID: 22622456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic control of sodium excretion in the distal nephron by inhibitory purinergic regulation of the epithelial Na(+) channel.
    Toney GM; Vallon V; Stockand JD
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):52-60. PubMed ID: 22143248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purinergic inhibition of ENaC produces aldosterone escape.
    Stockand JD; Mironova E; Bugaj V; Rieg T; Insel PA; Vallon V; Peti-Peterdi J; Pochynyuk O
    J Am Soc Nephrol; 2010 Nov; 21(11):1903-11. PubMed ID: 20813869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.
    Ubaid-Girioli S; Ferreira-Melo SE; Souza LA; Nogueira EA; Yugar-Toledo JC; Coca A; Moreno H
    J Clin Hypertens (Greenwich); 2007 Oct; 9(10):770-4. PubMed ID: 17917504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone biosynthesis, regulation, and classical mechanism of action.
    Williams GH
    Heart Fail Rev; 2005 Jan; 10(1):7-13. PubMed ID: 15947886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dibutyryl cyclic AMP on plasma renin activity in normal men and patients with primary aldosteronism.
    Fukuda N; Soma M; Kubo A; Kunimoto M; Watanabe Y; Izumi Y; Kanmatsuse K
    J Endocrinol Invest; 1997 Jan; 20(1):13-7. PubMed ID: 9075066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood volume changes and arginine vasotocin (AVT) blood concentration in conscious fresh water and salt water adapted ducks.
    Simon-Oppermann C; Gray D; Szczepanska-Sadowska E; Simon E
    Pflugers Arch; 1984 Feb; 400(2):151-9. PubMed ID: 6718220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial natriuretic peptide transcription, secretion, and glomerular receptor activity during mineralocorticoid escape in the rat.
    Ballermann BJ; Bloch KD; Seidman JG; Brenner BM
    J Clin Invest; 1986 Sep; 78(3):840-3. PubMed ID: 3018046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escape from the sodium-retaining action of intrarenal angiotensins II and III in the conscious dog.
    Dickstein GM; Woodson JF; Lamb NE; Rose CE; Peach MJ; Carey RM
    Endocrinology; 1985 Nov; 117(5):2160-9. PubMed ID: 4042980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escape from the sodium-retaining effects of mineralocorticoids: is there a role for dopamine?
    Coruzzi P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):455-8. PubMed ID: 8106635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems.
    Gonzalez-Campoy JM; Romero JC; Knox FG
    Kidney Int; 1989 Mar; 35(3):767-77. PubMed ID: 2523495
    [No Abstract]   [Full Text] [Related]  

  • 16. The renal escape from the sodium retaining effect of mineralocorticoids in spontaneously hypertensive rats.
    Elebute O
    West Afr J Pharmacol Drug Res; 1976 Dec; 3(2):111-7. PubMed ID: 1029906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the renal medulla in hypertension.
    Muirhead EE
    Adv Intern Med; 1974; 19():81-107. PubMed ID: 4360963
    [No Abstract]   [Full Text] [Related]  

  • 18. Escape from the sodium-retaining effects of mineralocorticoids.
    Knox FG; Burnett JC; Kohan DE; Spielman WS; Strand JC
    Kidney Int; 1980 Mar; 17(3):263-76. PubMed ID: 6995687
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.